Market Overview:
The global prokaryotic recombinant protein market is expected to grow at a CAGR of 10.5% during the forecast period from 2018 to 2030. The growth in this market can be attributed to the increasing demand for prokaryotic recombinant proteins from biotechnology companies, research institutes, contract research organizations (CROs), hospitals, and laboratories. North America is expected to dominate the global prokaryotic recombinant protein market during the forecast period followed by Europe and Asia Pacific. The growth in these regions can be attributed to factors such as rising R&D expenditure on life sciences, increasing number of CROs in these regions, and growing demand for prokaryotic recombinant proteins from hospitals and laboratories.
Product Definition:
A prokaryotic recombinant protein is a protein that is produced by a prokaryotic cell, such as bacteria, through the process of recombination. This process involves the combination of DNA from two different organisms into one molecule. The resulting protein may be composed of proteins from different sources or it may be a hybrid of two proteins. Prokaryotic recombinant proteins are important for many reasons, including their ability to produce large quantities of desired proteins and their potential use in biotechnology and pharmaceutical applications.
Hormones:
Hormones are chemical messengers that regulate various metabolic activities in the body. Hormone deficiency leads to diseases such as diabetes, thyroiditis, and growth retardation. The human body produces two main hormones - adrenal glands produce epinephrine (adrenaline) and pituitary gland produces oxytocin ( Pitocin). These hormones play an important role in controlling the menstrual cycle, pregnancy, growth & development of an individual along with maintaining blood pressure levels.
Interferons:
Interferons are a group of proteins that are produced in response to viral infections, cancer, and other stress factors. Interferons act as intercellular messengers that regulate various aspects of the immune response such as cell growth & differentiation, apoptosis (programmed cell death), cytokine production by white blood cells (neutrophils & monocytes). Interferon is used for the treatment of multiple sclerosis and cancer.
Application Insights:
The biotechnology companies segment dominated the global prokaryotic recombinant protein market in terms of revenue share in 2017. This is attributed to the rising number of R&D initiatives undertaken by major biotechnology companies for developing new products based on cytokine and interferon families. For instance, in March 2016, Cytiva announced completion of Phase 2 clinical trial for its recombinant human IFN-gamma product CpG (TLR 9 agonist) 1101 that targets and eliminates Helicobacter pylori infection. The company has received Orphan Designation from European Commission (EC) for its lead candidate under EUAs issued.
Infectious diseases are one of the major causes leading to death globally due to their high mortality rate coupled with their ability to cause significant disease burden & economic loss owing to extensive usage of advanced healthcare facilities & treatments across all regions including Europe, North America, Asia Pacific etc.
Regional Analysis:
North America dominated the global prokaryotic recombinant protein market in terms of revenue share in 2016. The presence of a large number of biotechnology companies and research institutes involved in drug discovery process is one major factor responsible for this dominance. In addition, the region has witnessed an increase in R&D spending on prokaryotic cell culture media over the past few years which is also expected to have a positive impact on regional growth during the forecast period.
Asia Pacific is anticipated to witness significant growth over the forecast period owing to increasing government funding for biopharmaceutical industry coupled with growing awareness among people regarding advanced healthcare facilities and treatments offered by these companies through biosimilars.
Growth Factors:
- Increasing demand for recombinant proteins in the biopharmaceutical industry for the development of novel therapeutics
- Growing prevalence of chronic diseases that require regular protein replacement therapy
- Proliferation of monoclonal antibody-based drugs and other biologic therapies
- Rising investment in R&D activities for prokaryotic recombinant protein discovery
- Technological advancements in expression systems and downstream purification processes
Scope Of The Report
Report Attributes
Report Details
Report Title
Prokaryotic Recombinant Protein Market Research Report
By Type
Hormones, Interferons, Interleukins, Others
By Application
Biotechnology Companies, Research institutes, Contract Research organizations, Hospital, Laboratories, Others
By Companies
Eli Lilly and Company, Merck, Roche, Prospec-Tany Technogene, Cusabio Technology, Randox Laboratories, Batavia Biosciences, Geno Technology, Kaneka and Eurogentec, Abnova Corporation, Cayman Chemical Company, Geltor IndieBio, Bioclone
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
186
Number of Tables & Figures
131
Customization Available
Yes, the report can be customized as per your need.
Global Prokaryotic Recombinant Protein Market Report Segments:
The global Prokaryotic Recombinant Protein market is segmented on the basis of:
Types
Hormones, Interferons, Interleukins, Others
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Biotechnology Companies, Research institutes, Contract Research organizations, Hospital, Laboratories, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Eli Lilly and Company
- Merck
- Roche
- Prospec-Tany Technogene
- Cusabio Technology
- Randox Laboratories
- Batavia Biosciences
- Geno Technology
- Kaneka and Eurogentec
- Abnova Corporation
- Cayman Chemical Company
- Geltor IndieBio
- Bioclone
Highlights of The Prokaryotic Recombinant Protein Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Hormones
- Interferons
- Interleukins
- Others
- By Application:
- Biotechnology Companies
- Research institutes
- Contract Research organizations
- Hospital
- Laboratories
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Prokaryotic Recombinant Protein Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Prokaryotic recombinant protein is a type of protein that is created in a laboratory by combining pieces of different proteins.
Some of the major companies in the prokaryotic recombinant protein market are Eli Lilly and Company, Merck, Roche, Prospec-Tany Technogene, Cusabio Technology, Randox Laboratories, Batavia Biosciences, Geno Technology, Kaneka and Eurogentec, Abnova Corporation, Cayman Chemical Company, Geltor IndieBio, Bioclone.
The prokaryotic recombinant protein market is expected to grow at a compound annual growth rate of 10.5%.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Prokaryotic Recombinant Protein Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Prokaryotic Recombinant Protein Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Prokaryotic Recombinant Protein Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Prokaryotic Recombinant Protein Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Prokaryotic Recombinant Protein Market Size & Forecast, 2020-2028
4.5.1 Prokaryotic Recombinant Protein Market Size and Y-o-Y Growth
4.5.2 Prokaryotic Recombinant Protein Market Absolute $ Opportunity
Chapter 5 Global Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Market Size Forecast by Type
5.2.1 Hormones
5.2.2 Interferons
5.2.3 Interleukins
5.2.4 Others
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Market Size Forecast by Applications
6.2.1 Biotechnology Companies
6.2.2 Research institutes
6.2.3 Contract Research organizations
6.2.4 Hospital
6.2.5 Laboratories
6.2.6 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Prokaryotic Recombinant Protein Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Prokaryotic Recombinant Protein Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Analysis and Forecast
9.1 Introduction
9.2 North America Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Market Size Forecast by Type
9.6.1 Hormones
9.6.2 Interferons
9.6.3 Interleukins
9.6.4 Others
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Market Size Forecast by Applications
9.10.1 Biotechnology Companies
9.10.2 Research institutes
9.10.3 Contract Research organizations
9.10.4 Hospital
9.10.5 Laboratories
9.10.6 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Analysis and Forecast
10.1 Introduction
10.2 Europe Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Market Size Forecast by Type
10.6.1 Hormones
10.6.2 Interferons
10.6.3 Interleukins
10.6.4 Others
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Market Size Forecast by Applications
10.10.1 Biotechnology Companies
10.10.2 Research institutes
10.10.3 Contract Research organizations
10.10.4 Hospital
10.10.5 Laboratories
10.10.6 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Market Size Forecast by Type
11.6.1 Hormones
11.6.2 Interferons
11.6.3 Interleukins
11.6.4 Others
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Market Size Forecast by Applications
11.10.1 Biotechnology Companies
11.10.2 Research institutes
11.10.3 Contract Research organizations
11.10.4 Hospital
11.10.5 Laboratories
11.10.6 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Analysis and Forecast
12.1 Introduction
12.2 Latin America Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Market Size Forecast by Type
12.6.1 Hormones
12.6.2 Interferons
12.6.3 Interleukins
12.6.4 Others
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Market Size Forecast by Applications
12.10.1 Biotechnology Companies
12.10.2 Research institutes
12.10.3 Contract Research organizations
12.10.4 Hospital
12.10.5 Laboratories
12.10.6 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Market Size Forecast by Type
13.6.1 Hormones
13.6.2 Interferons
13.6.3 Interleukins
13.6.4 Others
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Market Size Forecast by Applications
13.10.1 Biotechnology Companies
13.10.2 Research institutes
13.10.3 Contract Research organizations
13.10.4 Hospital
13.10.5 Laboratories
13.10.6 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Prokaryotic Recombinant Protein Market: Competitive Dashboard
14.2 Global Prokaryotic Recombinant Protein Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Eli Lilly and Company
14.3.2 Merck
14.3.3 Roche
14.3.4 Prospec-Tany Technogene
14.3.5 Cusabio Technology
14.3.6 Randox Laboratories
14.3.7 Batavia Biosciences
14.3.8 Geno Technology
14.3.9 Kaneka and Eurogentec
14.3.10 Abnova Corporation
14.3.11 Cayman Chemical Company
14.3.12 Geltor IndieBio
14.3.13 Bioclone
